Ross McNaughton

Ross is a partner in the Corporate Technology team, based in our Cambridge office.

Ross’s practice focuses on helping tech and life sciences companies in all aspects of their growth, capital raising and international expansion. He has extensive experience of a variety of venture financing and public capital raisings, mergers and acquisitions and general corporate advice, with a particular specialism in transactions with a transatlantic component.

Ross has extensive experience of transactions involving the US and was based out of San Francisco, CA in 2018 - 19. As a result, he has a particular expertise in supporting US investors and companies in their investment into the UK and elsewhere, as well as counselling UK companies looking to take investment from, or exit to, the US. He is an English qualified solicitor and registered foreign legal consultant in California.

Ross is the co-author of PLC’s leading article on M&A pricing structures: Pricing Mechanisms: locked box vs completion accounts.

CV ansehen CV ausblenden

Karriere

Since 2020	Partner, Taylor Wessing LLP
2015 - 2020	Partner, Penningtons Manches Cooper LLP, Cambridge
2010 - 2015	Partner, Paul Hastings LLP, London

2002 - 2009

Lawyer, Herbert Smith

Mehr Weniger

Ausbildung

2018	Admitted as a foreign legal consultant, state bar of California
2004	Admitted as a lawyer, England and Wales
2001	LPC and Post Graduate Degree in Law, Nottingham Law School

Publikationen

Crowdfunding: an alternative source of capital, PLC magazine, 2016

Cornerstone Investments in IPOs: the new normal for European markets?, PLC magazine, 2015

Pricing Mechanisms: locked box vs completion accounts, PLC magazine, 2012

Fremdsprachen

English

Expertise

Rechtsgebiete und Gruppen Gesellschaftsrecht/ M&A & Kapitalmärkte Venture Capital

Branchen Life Sciences & Healthcare Technology, Media & Communications

Referenzen

Oppilan and Zomagen on their sale to Ventyx as part of concurrent $114 million crossover financing	Oppilan Pharma Limited and Zomagen Biosciences Limited on their roll-up and sale into Ventyx Biosciences, Inc. and concurrent $114 million crossover financing led by venBio Partners. The transaction brings together three cutting-edge life sciences companies to create a clinical-stage biotechnology company developing immune modulators to treat inflammatory diseases and autoimmune disorders. Investors included Third Point and RTW Investments.
Various	Advising on various IPOs, including Incanthera, a life sciences company focused on revolutionising cancer therapies, and GRC International, based in Cambridge.
Akarna Therapeutics	Advising Akarna Therapeutics, a San Diego and Cambridge-based, biotech company, on its sale to Allergan.

US-based investor	Advising a US-based investor on its investment into CMR Surgical in Cambridge.
Topia	Advising US-headquartered Topia on various funding rounds and subsequent acquisition of Monaeo Inc.
Cambridge Innovation Capital	Advising Cambridge Innovation Capital on its investment in PetMedix